3 Matching Annotations
  1. Jun 2023
  2. prodikedokteran.fk.uns.ac.id prodikedokteran.fk.uns.ac.id
    Malignant Peripheral Nerve Sheath Tumor
    1
    1. sandraileana 27 Jun 2023
      Adjuvantradiotherapy ranging in dosage from 54 Gy to 62 Gy was administered to patients whoexhibited deep-seated, high-grade tumors that were larger than 5 cm

      Dosis y beneficio RT adyuvante TMVNP: * Dosis: 54-62 Gy en tumor profundo, alto grado, >5cm * Beneficio en SLE y SG a 5 años A 5 años: * SLE: 42% con RT vs 0% sin RT * SG: 65% con RT vs 38% sin RT

      RT PO TMVNP
    Visit annotations in context

    Tags

    Annotators

    URL

    prodikedokteran.fk.uns.ac.id/wp-content/uploads/2017/09/MPNST.pdf
  3. www.ncbi.nlm.nih.gov www.ncbi.nlm.nih.gov
    Malignant Peripheral Nerve Sheath Tumors—A Comprehensive Review of Pathophysiology, Diagnosis, and Multidisciplinary Management
    2
    1. sandraileana 27 Jun 2023
      radiotherapy is most useful in patients with large (e.g., >5 cm), high-grade tumors, and/or those with positive margins at resection

      Indicaciones RT adyuvante en TMVNP: * Tamaño >5cm * Alto grado * Margen positivo

      RT PO TMVNP
    2. sandraileana 27 Jun 2023
      used 45 Gy (25 fractions of 1.8 Gy) neoadjuvant radiotherapy to the primary site, followed by resection and adjuvant radiotherapy with the dose determined by the success of resection–10.8 Gy (6 fractions of 1.8 Gy) for microscopic residual disease R1 (cumulative dose 55. 8 Gy) or 19.8 Gy (11 fractions of 1.8 Gy) for gross residual disease/no resection (cumulative dose 64.8 Gy)

      RT neo: 45 Gy + RT PO: 10.8Gy/6fx en R1, 19.8Gy/11fx en R2

      RT neo TMVNP
    Visit annotations in context

    Tags

    Annotators

    URL

    ncbi.nlm.nih.gov/pmc/articles/PMC8774267/